Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Table 7 Adverse effects according to the value of the initial and maximal trough concentration (Cmin)

Adverse effects	No. of patients with initial C_min		P-value	No. of patients with maximal C_min		P-value
Adverse effects	< 20 μg/mL (n = 245)	≥20 μg/mL (n = 267)	P-value	< 20 μg/mL (n = 235)	≥20 μg/mL (n = 277)	P-value
Nephrotoxicity on the 4th day	7 (2.9%)	9 (3.4%)	0.739	7 (3.0%)	9 (3.2%)	0.861
Nephrotoxicity at the end of therapy	19 (7.8%)	21 (7.9%)	0.963	17 (7.2%)	23 (8.3%)	0.653
Hepatotoxicity on the 4th day	4 (1.6%)	4 (1.5%)	1.000	4 (1.7%)	4 (1.4%)	1.000
Hepatotoxicity at the end of therapy	7 (2.9%)	4 (1.5%)	0.366	7 (3.0%)	4 (1.4%)	0.360

ISSN: 2050-6511